Sugi Predict

Sugi Predict / Targets / AR

AR

Androgen receptor · P10275 · AR on Sugi Atlas →

409,373 patent compounds predicted against AR, 234,547 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Nilutamide Nilutamide (SCHEMBL12670) 1.00 15/20
Bicalutamide Bicalutamide (SCHEMBL3611) 1.00 9/20
(R)-Bicalutamide (R)-Bicalutamide (SCHEMBL3612) 1.00 9/20
Clocortolone Pivalate Clocortolone Pivalate (SCHEMBL5120) 1.00 9/20
SCHEMBL31349 SCHEMBL31349 0.49 9/20
Flutamide Flutamide (SCHEMBL3934) 1.00 8/20
Onapristone Onapristone (SCHEMBL8740) 1.00 8/20
Calusterone Calusterone (SCHEMBL4509) 0.62 8/20
Megestrol Acetate Megestrol Acetate (SCHEMBL745) 1.00 7/20
Chlormadinone Acetate Chlormadinone Acetate (SCHEMBL15046) 1.00 7/20
Nomegestrol Acetate Nomegestrol Acetate (SCHEMBL37517) 1.00 7/20
Chlormadinone Acetate Chlormadinone Acetate (SCHEMBL40360) 1.00 7/20
Diflucortolone Diflucortolone (SCHEMBL3794) 0.71 7/20
Diflucortolone Diflucortolone (SCHEMBL3795) 0.71 7/20
Diflucortolone Diflucortolone (SCHEMBL3796) 0.71 7/20
SCHEMBL6967 SCHEMBL6967 0.71 7/20
Diflucortolone 21-Valerate Diflucortolone 21-Valerate (SCHEMBL3015) 0.63 7/20
Diflucortolone 21-Valerate Diflucortolone 21-Valerate (SCHEMBL13157) 0.63 7/20
Diflucortolone 21-Valerate Diflucortolone 21-Valerate (SCHEMBL13158) 0.63 7/20
Promegestone Promegestone (SCHEMBL37770) 0.59 7/20

Clinical trials — most relevant to AR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer PHASE3ACTIVE_NOT_RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response PHASE3RECRUITING
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC PHASE2RECRUITING
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients PHASE1/PHASE2UNKNOWN
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies PHASE2COMPLETED
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer PHASE2COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Bipolar Androgen Therapy + Carboplatin in mCRPC PHASE2RECRUITING
Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer PHASE2UNKNOWN
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer PHASE2NOT_YET_RECRUITING
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer PHASE2COMPLETED
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) PHASE2RECRUITING
Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers PHASE2COMPLETED
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients PHASE2COMPLETED
Sequencing Abiraterone and Enzalutamide in mCRPC PHASE2COMPLETED
Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients nanUNKNOWN
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION nanUNKNOWN
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Study of Prostate Cancer in Black and White U.S. Veterans nanCOMPLETED
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? nanUNKNOWN
Early Mental Response - The EMRE Study nanRECRUITING
Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database nanCOMPLETED
INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer nanUNKNOWN
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity nanRECRUITING
Anti-Androgen Treatment for COVID-19 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AR binder may also engage these)

ProteinNameSimilarity
O97775 — 1.000 O97775 →
O97960 — 1.000 O97960 →
O97952 — 1.000 O97952 →
Q6QT55 — 1.000 Q6QT55 →
P19091 — 1.000 P19091 →
Q9TT90 — 1.000 Q9TT90 →
Q9GKL7 — 1.000 Q9GKL7 →
O97776 — 1.000 O97776 →
Q8MIK0 — 1.000 Q8MIK0 →
P49699 — 0.997 P49699 →
P15207 — 0.995 P15207 →
PGR Progesterone receptor 0.994 landscape →
Q92858 — 0.994 Q92858 →
P06537 — 0.994 P06537 →
A7X8B7 — 0.994 A7X8B7 →
A2D4R4 — 0.994 A2D4R4 →
P14653 — 0.993 P14653 →
Q2VWA4 — 0.993 Q2VWA4 →
A7X8B3 — 0.993 A7X8B3 →
P07812 — 0.993 P07812 →
Q8BX46 — 0.993 Q8BX46 →
A2T7J2 — 0.993 A2T7J2 →
NR4A3 Nuclear receptor subfamily 4 group A member 3 0.993 landscape →
A7X8D4 — 0.993 A7X8D4 →
Q63449 — 0.993 Q63449 →
A7X8C9 — 0.993 A7X8C9 →
P06536 — 0.993 P06536 →
P06186 — 0.992 P06186 →
A7XW16 — 0.992 A7XW16 →
P84551 — 0.992 P84551 →